Skip to main content

Current Therapy of Chronic Liver Disease

Summary

The study of chronic liver disease has been hampered by insufficient information relative to the pathogenesis of the many forms of hepatitis. Consequently, well-designed treatment strategies are frequently lacking. Wilson’s disease is characterised by excessive copper accumulation in the liver and other organs. While d-penicillamine is clearly effective, many patients may not tolerate its many adverse effects. Trientine, oral zinc and unithiol have all shown promise as therapeutic alternatives.

Autoimmune chronic active hepatitis responds well to prednisone and azathioprine. Cyclosporin has also produced clinical improvement in several case reports but no comparison has yet been made with the current standard therapy. Recombinant interferon-α (IFNα) has demonstrated the ability to inhibit hepatitis B viral replication, and the combination of oral corticosteroids followed by IFNα is more effective than either agent alone in eliminating viral replication in patients with chronic active hepatitis B.

Currently, primary sclerosing cholangitis (PSC) has no standard medical management, but corticosteroids and methotrexate may each have a future role in its treatment. Drug treatment for primary biliary cirrhosis (PBC) has been disappointing, and early reports of success with d-penicillamine were not confirmed in large well-controlled trials. While some reports of improvement with several agents have been described, larger studies are still needed.

Alcoholic liver disease continues to be associated with significant morbidity and mortality and numerous investigators have researched several different medical avenues of treatment. Success reported with androgens and the antithyroid agent propylthiouracil in alcoholic liver disease will need confirmation by other research before these agents can be recommended for routine use. Finally, colchicine may prove to be effective in slowing the rate of fibrosis in cirrhosis, but this has yet to be conclusively proven.

This is a preview of subscription content, access via your institution.

References

  • Abonyi M, Kisfaludy S, Szalay F. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis. Acta Physiologica Hungarica 64(3–4): 455–460, 1984

    PubMed  CAS  Google Scholar 

  • Alexander GJM, Fagan EA, Daniels HM, Brahm J, Smith HM, et al. Loss of HbsAG with interferon therapy in chronic hepatitis B virus infection. Lancet 2: 66, 1987

    PubMed  Article  CAS  Google Scholar 

  • Alexander GJM, Fagan EA, Hegarty JE, Rolando N, Guarner P, et al. A controlled trial of acyclovir in stable chronic HbsAg, HBeAg positive carriers. Journal of Hepatology 3 (Suppl. 2): S123–127, 1986

    PubMed  Article  Google Scholar 

  • Alexander GJM, Fagan EA, Rolando N, Guarner P, Callender ME, et al. Differential effect of ARA-AMP ON serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection: a possible reason for lack of efficacy. Journal of Hepatology 3 (Suppl. 2): S81–86, 1986

    PubMed  Article  Google Scholar 

  • Anderson MG, Harrison TJ, Alexander G, Zuckerman AJ, Murray-Lyon IM. Randomized controlled trial of lymphoblastoid interferon for chronic hepatitis B. Gut 28: 619–622, 1987

    PubMed  Article  CAS  Google Scholar 

  • Barbara L, Mazzella G, Baraldina M, Gasbarrini G, Giungi F, et al. A randomized controlled trial with human lymphoblastoid interferon vs no treatment in chronic hepatitis B virus infection. Hepatology 3 (Suppl. 2): S235–S238, 1986

    Google Scholar 

  • Bodenheimer H, Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 95: 124–129, 1988

    PubMed  Google Scholar 

  • Bodenheimer HC, Schaffner F, Sternlieb I, Klion FM, Vernace S, et al. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5(6): 1139–1142, 1985

    PubMed  Article  Google Scholar 

  • Brenner DA, Chojkier M. Therapeutic strategies for hepatic fibrosis. Hepatology 8(1): 176–182, 1988

    PubMed  Article  Google Scholar 

  • Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, et al. Treatment of Wilson’s disease with zinc III: prevention of reaccumulation of hepatic copper. Journal of Laboratory and Clinical Medicine 109(5): 526–530, 1987

    PubMed  CAS  Google Scholar 

  • Burgert S, Brown B, Kirkpatrick R, LaBrecque D. Positive corticosteroid response in early primary sclerosing cholangitis. Gastroenterology 86(5, part 2): 1037, 1984

    Google Scholar 

  • Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology 1: 141–151, 1985

    PubMed  Article  CAS  Google Scholar 

  • Christensen E, et al. Prognostic value of child-turcotte criteria in medically treated cirrhosis. Hepatology 4: 430–435, 1984

    PubMed  Article  CAS  Google Scholar 

  • Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final result of an international trial. Gastroenterology 89: 1084–1091, 1985

    PubMed  CAS  Google Scholar 

  • Cooksley RA, Bradbear JW, Halliday JS, Powell LW. Chronic hepatitis: aetiology and current management. Drugs 27: 579–584, 1984

    PubMed  Article  CAS  Google Scholar 

  • Copenhagen Study Group for Liver Disease. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 6(5): 807–813, 1986

    Article  Google Scholar 

  • Czaja A, Dickson ER. Chronic active hepatitis: the Mayo Clinic experience, Marcel Dekker Inc., New York, 1986

    Google Scholar 

  • Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, et al. Trial of penicillamine in advanced primary biliary cirrhosis. New England Journal of Medicine 312(16): 1011–1015 1985

    PubMed  Article  CAS  Google Scholar 

  • Diehl AM, Boitnott JK, Herlong HF, Potter JJ, Van Duyn MA, et al. Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology 5(1): 57–63, 1985

    PubMed  Article  CAS  Google Scholar 

  • Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, et al. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology 90: 150–157, 1986

    PubMed  CAS  Google Scholar 

  • Dusheiko G, Dibisceglie A, Bowyer S, Sachs E, Ritchie M, et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5(4): 556–560, 1985

    PubMed  Article  CAS  Google Scholar 

  • Fattovich G, Brollo L, Pontisso P, Pornaro E, Rugge M, et al. Levamisole therapy in chronic type B hepatitis. Gastroenterology 91: 692–696, 1986

    PubMed  CAS  Google Scholar 

  • Garcia G, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: a randomized, double-blinded, placebo-controlled trial. Annals of Internal Medicine 107: 278–285, 1987

    PubMed  CAS  Google Scholar 

  • Gluud C, Christofferson P, Eriksen J, Wantzin P, Knudsen BB, et al. No effect of long-term oral testosterone treatment on liver morphology in men with alcoholic cirrhosis. American Journal of Gastroenterology 82(7): 660–664, 1987

    PubMed  CAS  Google Scholar 

  • Gluud C, et al. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 6(5) 807–813, 1986

    Article  Google Scholar 

  • Grijm R, Huibregtse K, Bartelsman J, Mathus-Vliegen M, Dekker W, et al. Therapeutic investigations in primary sclerosing cholangitis. Digestive Diseases and Sciences 31(8): 792–798, 1986

    PubMed  Article  CAS  Google Scholar 

  • Guarascio P, De Felici AP, Migliorini D, Alexander GJM, Fagan EA, et al. Treatment of chronic HbeAg-positive hepatitis with acyclovir: a controlled trial. Journal of Hepatology 3 (Suppl. 12): S143–S147, 1986

    PubMed  Article  Google Scholar 

  • Halmy L, David K, Nagy I, Stotz G, Keleman JT. Clinical enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (catergen) treatment. Acta Physiologica Hungarica 64(3–4): 461–470, 1984

    PubMed  CAS  Google Scholar 

  • Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson’s Disease with zinc. I: Oral zinc therapy regimens. Hepatology 7(3): 522–528, 1987

    CAS  Google Scholar 

  • Hoofnagle JH. Therapy of chronic type B hepatitis with adenine arabinoside and adenine arabinoside monophosphate. Journal of Hepatology 3 (Suppl. 2): S73–S80, 1986

    PubMed  Article  Google Scholar 

  • Hoofnagle JH. Correspondence. Levamisole therapy in chronic type hepatitis. Hepatology 7: 598, 1987

    Google Scholar 

  • Hoofnagle JH, Davis GL, Hanson RG, Pappas SC, Peters MG, et al. Treatment of chronic type B hepatitis with multiple tenday courses of adenine arabinoside monophosphate. Journal of Medical Virology 15: 121–128, 1985

    PubMed  Article  CAS  Google Scholar 

  • Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, et al. A short course of prednisolone in chronic type B hepatiitis: report of a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 104: 12–17, 1986

    PubMed  CAS  Google Scholar 

  • Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91: 1327–1334, 1986

    PubMed  CAS  Google Scholar 

  • Hoofnagle JH, et al. Randomized controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95: 1318–1325, 1988

    PubMed  CAS  Google Scholar 

  • Hoogenraad TU, Van den Hamer CJA, Van Hattum J. Effective treatment of Wilson’s disease with oral zinc sulphate: two case reports. British Medical Journal 289: 273–276, 1984

    PubMed  Article  CAS  Google Scholar 

  • Hoogenraad TU, Van Hattum J, Van den Hamer CJA. Management of Wilson’s disease with zinc sulphate experience in a series of 27 patients. Journal of Neurological Sciences 77: 137–146, 1987

    Article  CAS  Google Scholar 

  • Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 93: 890–893, 1987

    PubMed  CAS  Google Scholar 

  • Kakumu S, Fuji A, Yoshioka K, Tahara H, Ohtani Y, et al. Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 8(3): 487–492, 1988

    PubMed  Article  CAS  Google Scholar 

  • Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, et al. A prospective trial of colchicine for primary biliary cirrhosis. New England Journal of Medicine 315(23): 1448–1454, 1986

    PubMed  Article  CAS  Google Scholar 

  • Kaplan M, Arora S, Pincus S. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Annals of Internal Medicine 106: 231–235, 1987

    PubMed  CAS  Google Scholar 

  • Kaplan MM, Knox TA, Arora S. Low-dose oral pulse methotrexate in the treatment of primary biliary cirrhosis (PBC): resolution of symptoms and improvement in biochemical tests of liver function. Abstract. Gastroenterology 94(5 part 2): A552, 1988

    Google Scholar 

  • Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo RP, Gent M, et al. Colchicine in the treatment of cirrhosis of the liver. New England Journal of Medicine 318(26): 1709–1713, 1988

    PubMed  Article  CAS  Google Scholar 

  • Kumada H, Ikeda K, Hoshida A, Seto S, Tsukada T, et al. Short-term prednisolone for inducing seroconversion from hepatitis Be antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B. Japanese Journal of Medicine 26(2): 217–221, 1987

    PubMed  Article  CAS  Google Scholar 

  • LaRusso N, Wiesner R, Ludwig J, MacCarty R. Current concepts in primary sclerosing cholangitis. New England Journal of Medicine 310(14): 899–903, 1984

    PubMed  Article  CAS  Google Scholar 

  • LaRusso N, Wiesner R, Ludwig J, MacCarty R, Beaver S, et al. Randomized trial of penicillamine in primary sclerosing cholangitis. Hepatology 6 (5), 1986

  • Lashner BA, Baker AL. Propylthiouracil for alcoholic liver disease. New England Journal of Medicine 318(22): 1471, 1988

    Article  Google Scholar 

  • Lashner B, Kane S, Hanauer S. Improved survival and delayed colectomy of patients with ulcerative colitis (UC) followed in a cancer (Ca) screening program. Gastroenterology 92, 1987

  • Leiser A, Kadish U. Beneficial effect of colchicine in a case of sclerosing cholangitis. American Journal of the Medical Sciences 291(6): 416–418, 1986

    PubMed  Article  CAS  Google Scholar 

  • Lindor K, Wiesner R, LaRusso N. Recent advances in the management of primary sclerosing cholangitis. Seminars in Liver Disease 322-327, 1987

  • Lipsky MA, Gollan JL. Treatment of Wilson’s Disease: in D-penicillamine we trust — what about zinc? Hepatology 7(3): 593–595, 1987

    PubMed  Article  CAS  Google Scholar 

  • Lok ASF, et al. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2: 298, 1988

    PubMed  Article  CAS  Google Scholar 

  • Loke RHT, Anderson MG, Coleman JC, Tsiquaye KN, Zuckerman AJ, et al. Suramin treatment for chronic active hepatitis B: toxic and ineffective. Journal of Medical Virology 21: 97–99, 1987

    PubMed  Article  CAS  Google Scholar 

  • Manns MP, Nakamura RM. Autoimmune liver disease. Clinics in Laboratory Medicine 8(2): 281–301, 1988

    PubMed  CAS  Google Scholar 

  • McDonald JA, Caruso L, Karayiannia P, Scully LJ, Harris JRW, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 7(4): 719–723, 1987

    PubMed  Article  CAS  Google Scholar 

  • Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine 311(223): 1464–1470, 1984

    PubMed  Article  CAS  Google Scholar 

  • Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, et al. VA Cooperative Study on Alcoholic Hepatitis. III. Changes in protein calorie malnutrition associated with 30 days of hospitalization with and without enterai nutritional therapy. Journal of Parenteral and Enterai Nutrition 9(5): 590–596, 1985

    Article  CAS  Google Scholar 

  • Minuk G, Bohme C, Burgess E, Hershfield N, Kelly J, et al. A prospective double-blind, randomized, controlled trial of cyclosporin in primary biliary cirrhosis. Abstract. Hepatology 7(5): 1119, 1987

    Google Scholar 

  • Mistilis SP, Vikers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Medical Journal of Australia 143: 463–465, 1985

    PubMed  CAS  Google Scholar 

  • Mitchison HC, Bassendine MF, Recored CO, Malcolm A, Watson A, et al. Controlled trial of prednisone for primary biliary cirrhosis (PBC): good for the liver, bad for the bones? Abstract. Hepatology 6(5): 1211, 1986

    Google Scholar 

  • Nair V, Tong MJ, Stevenson D, Roskamp D, Boone C, et al, A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Hepatology 6(6): 1319–1324, 1986

    PubMed  Article  CAS  Google Scholar 

  • Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, et al. Double blind controlled trial of D-penicillamine in patients with primary biliary cirrhosis. Gut 26: 114–119, 1985

    PubMed  Article  CAS  Google Scholar 

  • Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine 317(23): 1421–1427, 1987

    PubMed  Article  CAS  Google Scholar 

  • Par A, Horvath T, Bero T, Kada I, Pakodi F, et al. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (catergen) in chronic alcoholic liver disease. Acta Physiologica Hungarica 64(3-4): 449–454, 1985

    Google Scholar 

  • Perrillo RP. The use of cortiocosteroids in conjunction with antiviral therapy in chronic hepatitis B with ongoing viral replication. Journal of Hepatology 3 (Suppl. 2): S57–S64, 1986

    PubMed  Article  Google Scholar 

  • Perrillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, et al. Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780–786, 1985

    PubMed  CAS  Google Scholar 

  • Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: a randomized, controlled trial. Annals of Internal Medicine 109(2): 95–100, 1988

    PubMed  CAS  Google Scholar 

  • Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1: 834–836, 1987

    PubMed  Article  CAS  Google Scholar 

  • Rojkind M, Mourelle M, Kershenobich D. Anti-inflammatory and antifibrogenic activities of colchicine: treatment of liver cirrhosis. In Berk PD et al. (Eds) Myelofibrosis and the biology of connective tissue, pp. 475–489, Alan R. Liss, Inc., New York, 1984

    Google Scholar 

  • Romeo F, Palmisano L, Arcoria D. Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis: controlled-clinic trial — two years follow-up. Drug Research 37(1): 450, 1987

    PubMed  CAS  Google Scholar 

  • Schalm SW, van Buuren HR, Heytink RA, de Man RA. Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet 2: 358, 1985

    PubMed  Article  CAS  Google Scholar 

  • Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. New England Journal of Medicine 317(4): 211–213, 1987

    Article  Google Scholar 

  • Scully LJ, Shein R, Karahiannia R, McDonald JA, Thomas HC. Lymphoblastoid interferon therapy of chronic HBV infection: a comparison of 12 vs 24 weeks of thrice weekly treatment. Journal of Hepatology 5: 51–58, 1987

    PubMed  Article  CAS  Google Scholar 

  • Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomized controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1: 668–670, 1985

    PubMed  Article  CAS  Google Scholar 

  • Tage-Jensen U, Schlichting P, Thomsen HF, Høybye G, Thomsen AAC. Malignancies following long-term azathioprine treatment for chronic liver disease: a report from the Copenhagen Study Group for Liver Diseases. Liver 7: 81–83, 1987

    PubMed  CAS  Google Scholar 

  • Thomas HC, Scully LJ, Lever AML, Yap I, Pignatelli M. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital Studies of hepatitis B virus carrier treatment: identification of factors influencing response rates. Infection 15 (Suppl. 1): S26–S31, 1987

    PubMed  Article  Google Scholar 

  • Tong MJ, Liu S, Co RL. Persistence of serum hepatitis B virus deoxyribonucleic acid in hepatitis B surface antigen-positive patients with chronic persistent hepatitis treated with prednisone. Gastroenterology 92: 862, 1987

    PubMed  CAS  Google Scholar 

  • Trepo C, Ouzan D, Fontanges T, Chevallier M, Chossegros P, et al. Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV. Journal of Hepatology 3 (Suppl. 2): S97–S105, 1986

    PubMed  Article  Google Scholar 

  • Vogel W, Kathrein H, Judmaier G, Braunsteiner H. Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid. Correspondence. Lancet 1: 1163, 1988

    Article  CAS  Google Scholar 

  • Walshe JM. Unithiol in Wilson’s Disease. British Medical Journal 290: 673–674, 1985

    PubMed  Article  CAS  Google Scholar 

  • Walshe JM. The management of pregnancy in Wilson’s disease treated with trientine. Journal of Medicine (New Series) 58(225): 87, 1986

    Google Scholar 

  • Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxychlic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 27: 95–131, 1984

    PubMed  Article  CAS  Google Scholar 

  • Warnes TW. Treatment of primary biliary cirrhosis. Seminars in Liver Disease 5(3): 228–240, 1985

    PubMed  Article  CAS  Google Scholar 

  • Warnes TW. Smith A, Lee FI, Haboubi NY, Johnson PJ, et al. A controlled trial of colchicine in primary biliary cirrhosis: trial design and preliminary report. Journal of Hepatology 5: 1–7, 1987

    PubMed  Article  CAS  Google Scholar 

  • Weller IVD. A randomized controlled trial of adenine arabinoside 5′-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Journal of Hepatology 3 (Suppl. 2): S107–S110, 1986

    PubMed  Article  Google Scholar 

  • Wiesner RH, et al. A controlled clinical trial evaluating cyclosporin in the treatment of primary biliary cirrhosis: a preliminary report. Hepatology 7(5): 1025, 1987

    Google Scholar 

  • World MJ, Aps EJ, Shaw GK, Thomson AD. (+)-cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial. Alcohol and Alcoholism 19(1): 23–29, 1984

    PubMed  CAS  Google Scholar 

  • World MJ, Ryle PR, Aps EJ, Shaw GK, Thomson AD. Palmitoylcatechin for alcoholic liver disease: results of a three-month clinical trial. Alcohol and Alcoholism 22(4): 331–340, 1987

    PubMed  CAS  Google Scholar 

  • Yokosuka O, Omata M, Imazeki F, Hirota, Mori J, et al. Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B: a controlled study. Gastroenterology 89: 246–251, 1985

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stavinoha, M.W., Soloway, R.D. Current Therapy of Chronic Liver Disease. Drugs 39, 814–840 (1990). https://doi.org/10.2165/00003495-199039060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199039060-00002

Keywords

  • Colchicine
  • Chronic Liver Disease
  • Primary Biliary Cirrhosis
  • Primary Sclerosing Cholangitis
  • Alcoholic Liver Disease